Novo Nordisk (NYSE: NVO) has a couple of fantastic products in Wegovy and Ozempic. While only Wegovy is approved for treating weight loss, both products have been effective in helping people shed pounds, resulting in Novo Nordisk struggling to meet what has been scorching-hot demand.

And there could be yet another product that to generate even more demand, and perhaps be Novo's best weight-loss product yet.

In clinical trials, Wegovy has demonstrated that, on average, it can help patients lose about 15% of their body weight. But one of the downsides is that it is an injectable treatment (as is Ozempic), so it may not be as appealing to patients as a pill.

Continue reading

Source Fool.com